Caris Life Sciences, Inc. (CAI)

Market Cap	5.24B
Revenue (ttm)	649.06M +112.0%
Net Income	-681.86M
EPS	-6.48
Shares Out	282.15M
PE Ratio	n/a
Forward PE	96.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,303,308
Open	18.50
Previous Close	18.31
Day's Range	18.21 - 18.98
52-Week Range	17.15 - 42.50
Beta	n/a
Analysts	Strong Buy
Price Target	33.63 (+81.1%)
Earnings Date	Feb 26, 2026

About CAI

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising lab...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2025
• Employees: 1,769
• Stock Exchange: NASDAQ
• Ticker Symbol: CAI
• Website: https://www.carislifesciences.com

Financial Performance

In 2024, Caris Life Sciences's revenue was $412.26 million, an increase of 34.67% compared to the previous year's $306.13 million. Losses were -$378.26 million, -18.22% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for CAI stock is "Strong Buy." The 12-month stock price target is $33.63, which is an increase of 81.10% from the latest price.

Price Target

$33.63

(81.10% upside)

Analyst Consensus: Strong Buy